Data from IMpower 130, IMpower 132, and IMpower 150 confirm that combining atezolizumab with chemotherapy is the best first-line treatment in advanced NSCLC when anti-PD-L1 therapy is indicated.
The rise of immunotherapy in cancer care has brought with it the challenge of managing adverse events (AEs). But immune-related AEs are known to be a sign that the treatment is working, and an pooled analysis of phase 3 trials involved atezolizumab (Tecentriq), presented during the 2021 American Society of Clinical Oncology Annual Meeting, show that the presence of low-grade AEs can, in fact, predict longer overall survival (OS).
Atezolizumab is currently approved in the first- and second-line settings for advanced non-small cell lung cancer (NSCLC). In an exploratory analysis, investigators pooled data from the IMpower 130, the IMpower 132, and the IMpower 150 studies, which evaluated the anti-PD-L1 agent in various combinations in treatment-naïve patients with nonsquamous stage IV NSCLC. The combinations were:
Analyses of immune-related AEs and survival took place at 1, 3, 6, and 12 months. In total, 2503 patients were included; 1577 in the atezolizumab arm and 926 in the control arm. Study protocols called for treatment interruption or discontinuation of AEs were grade 3 or higher.
Results showed:
The authors concluded that patients with grade 1 and 2 immune-related AEs had the longest OS and those with grade 3 or higher had the shortest, possibly due to discontinuation of therapy. They wrote that the data offer additional support for atezolizumab with chemotherapy in the first-line setting, with or without bevacizumab.
F. Hoffman-LaRoche funded the study.
Reference
Socinski MA, Jotte RM, Cappuzzo F, et al. Pooled analyses of immune-related adverse events (irAEs) and efficacy from thephase 3 trials IMpower130, IMpower132, and IMpower150. J Clin Oncol. 2021; 39(Suppl_15): abstr 9002. DOI: 10.1200/JCO.2021.39.15_suppl.9002
Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs
May 18th 2024Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs
May 18th 2024Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
2 Commerce Drive
Cranbury, NJ 08512